rethinkTHC Search
Menu
Study breakdown

Review of Cannabinoids for Multiple Sclerosis and the Emerging Field of Nano-Cannabinoid Medicine

Narrative ReviewPreliminary evidence
The takeaway

This review highlights cannabinoids' potential as more than symptomatic treatment for MS, examining how nanotechnology may improve delivery.

MS patients, neurologists, and cannabinoid pharmacology researchers.

CBD identified as antagonist against pro-inflammatory cytokines in MS

What the researchers found

Cannabinoids demonstrate anti-inflammatory, neuroprotective, and immunosuppressive properties relevant to MS. Nano-delivery systems may reduce toxicity.

Why it matters

MS has no universally effective treatment. Nanotechnology could overcome current limitations of cannabinoid medications.

The numbers in context

170 articles reviewed; CBD mechanisms: TNF-alpha downregulation, BDNF mRNA restoration, serotonin recovery

How the study worked

Narrative review of 170 articles from PubMed, Web of Science, and Scopus.

What this study cannot tell us

Narrative review. Mostly preclinical evidence. No new clinical data.

How to read the evidence

Narrative review of mostly preclinical evidence.

When this study was published

Published in 2024.

The bigger picture

Cannabinoids as disease-modifying agents for MS is still largely theoretical. Nano-delivery is the next frontier.

Questions still open

  • Can nano-cannabinoids demonstrate superior efficacy in trials?
  • What markers predict cannabinoid therapy response in MS?

Common questions

Could cannabinoids slow MS progression?
Preclinical evidence suggests potential but clinical trials are needed.
What is nano-cannabinoid medicine?
Nanotechnology-based cannabinoid delivery for reduced side effects.

Read the original research

Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine.

Pharmaceutics, 16(2)

Citation

Nouh, Roua A; Kamal, Ahmed; Oyewole, Oluwaseyi; Abbas, Walaa A; Abib, Bishoy; Omar, Abdelrouf; Mansour, Somaia T; Abdelnaser, Anwar. (2024). Unveiling the Potential of Cannabinoids in Multiple Sclerosis and the Dawn of Nano-Cannabinoid Medicine.. Pharmaceutics, 16(2). https://doi.org/10.3390/pharmaceutics16020241

Explore the wider topic